Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis

被引:6
作者
Elhalag, Rowan H. [1 ]
Motawea, Karam R. [1 ]
Talat, Nesreen Elsayed [1 ]
Rouzan, Samah S. [1 ]
Shah, Jaffer [2 ]
机构
[1] Alexandria Univ, Fac Med, Alexandria, Egypt
[2] New York State Dept Hlth, New York, NY 12237 USA
来源
FRONTIERS IN NEUROLOGY | 2023年 / 14卷
关键词
Duchene muscular dystrophy (DMD); vamorolone; neuromuscular; glucocorticoids; steroid naive; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; BONE TURNOVER; CELLS PROMOTE; DEFLAZACORT; CHILDREN; VBP15; CORTICOSTEROIDS; PREDNISOLONE; PATHOLOGY;
D O I
10.3389/fneur.2023.1107474
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and aim: Recent studies evaluated the role of vamorolone in treating Duchenne muscular dystrophy (DMD), so we aimed in our Meta-analysis to assess the efficacy of vamorolone in comparison with placebo and corticosteroids for treating DMD patients.Methods: We searched PubMed, Web of Science, Scopus, and Cochrane library databases. We included any randomized control trials and controlled observational studies that investigated the role of vamorolone in treating DMD patients. We used RevMan software, version 5.4. to perform our meta-analysis.Results: After a search of the literature, 4 studies were included in the meta-analysis; the total number of patients included in the study is 277 patients, 125 patients in the vamorolone group, 106 in the glucocorticoids group, and 46 in placebo (steroid naive) group. The pooled analysis showed a statistically significant association between the vamorolone group and increased TTSTAND velocity, TTRW velocity and TTCLIMB velocity compared with the placebo group (MD = 0.04, 95% CI = 0.02-0.07, p = 0.002), (MD = 0.24, 95% CI = 0.11-0.37, p = 0.0003), and (MD = 0.06, 95% CI = 0.05-0.06, p < 0.00001), respectively. Also, the analysis showed a statistically significant association between vamorolone and increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid group (MD = -0.14, 95% CI = -0.26 to -0.01, p = 0.03) and (MD = 17.82, 95% CI = 3.89-31.75, p = 0.01), respectively.Conclusion: Our study revealed a significant association between vamorolone and increased TTSTAND velocity, TTRW velocity, and TTCLIMB velocity compared with the placebo (steroid naive), also showed a statistically significant association between increased TTRW velocity and increased Height percentile for age compared with the glucocorticoid that enhances the privilege of vamorolone over glucocorticoid in treating DMD patients. More multicenter randomized studies are needed to support our results.
引用
收藏
页数:9
相关论文
共 38 条
  • [1] Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule
    Aartsma-Rus, Annemieke
    Van Deutekom, Judith C. T.
    Fokkema, Ivo F.
    Van Ommen, Gert-Jan B.
    Den Dunnen, Johan T.
    [J]. MUSCLE & NERVE, 2006, 34 (02) : 135 - 144
  • [2] Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy
    Acharyya, Swarnali
    Villalta, S. Armando
    Bakkar, Nadine
    Bupha-Intr, Tepmanas
    Janssen, Paul M. L.
    Carathers, Micheal
    Li, Zhi-Wei
    Beg, Amer A.
    Ghosh, Sankar
    Sahenk, Zarife
    Weinstein, Michael
    Gardner, Katherine L.
    Rafael-Fortney, Jill A.
    Karin, Michael
    Tidball, James G.
    Baldwin, Albert S.
    Guttridge, Denis C.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (04) : 889 - 901
  • [3] Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects
    Babadjanova, G
    Allolio, B
    Vollmer, M
    Reincke, M
    Schulte, HM
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (01) : 53 - 57
  • [4] Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study
    Bello, Luca
    Gordish-Dressman, Heather
    Morgenroth, Lauren P.
    Henricson, Erik K.
    Tina Duong
    Hoffman, Eric P.
    Cnaan, Avital
    McDonald, Craig M.
    [J]. NEUROLOGY, 2015, 85 (12) : 1048 - 1055
  • [5] Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade
    Biggar, WD
    Harris, VA
    Eliasoph, L
    Alman, B
    [J]. NEUROMUSCULAR DISORDERS, 2006, 16 (04) : 249 - 255
  • [6] Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy
    Buyse, Gunnar M.
    Goemans, Nathalie
    van den Hauwe, Marleen
    Meier, Thomas
    [J]. PEDIATRIC PULMONOLOGY, 2013, 48 (09) : 912 - 920
  • [7] Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy
    Chen, YW
    Nagaraju, K
    Bakay, M
    McIntyre, O
    Rawat, R
    Shi, R
    Hoffman, EP
    [J]. NEUROLOGY, 2005, 65 (06) : 826 - 834
  • [8] Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset
    Damsker, Jesse M.
    Cornish, Michaelyn R.
    Kanneboyina, Priya
    Kanneboyina, Ila
    Yu, Qing
    Lipson, Rachel
    Phadke, Aditi
    Knoblach, Susan M.
    Panchapakesan, Karuna
    Morales, Melissa
    Fiorillo, Alyson A.
    Partridge, Terence
    Nagaraju, Kanneboyina
    [J]. INFLAMMATION RESEARCH, 2019, 68 (11) : 969 - 980
  • [9] Regulation of phosphatidylinositol 3-kinase (Pl3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch
    Dogra, Charu
    Changotra, Harish
    Wergedal, Jon E.
    Kumar, Ashok
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 208 (03) : 575 - 585
  • [10] 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy
    Fenton, C. G.
    Doig, C. L.
    Fareed, S.
    Naylor, A.
    Morrell, A. P.
    Addison, O.
    Wehmeyer, C.
    Buckley, C. D.
    Cooper, M. S.
    Lavery, G. G.
    Raza, K.
    Hardy, R. S.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)